

*Hong Kong Exchanges and Clearing Limited and The Stock of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss however arising from or in reliance upon the whole or any part of the contents of this announcement.*



**Abbisko Cayman Limited**  
**和譽開曼有限責任公司**

*(Incorporated in the Cayman Islands with limited liability)*  
**(Stock Code: 2256)**

**VOLUNTARY ANNOUNCEMENT**

Abbisko Cayman Limited (the “**Company**”, together with its subsidiaries, the “**Group**”) hereby informs the shareholders and potential investors of the Company of the attached press release that a subsidiary of the Company, Abbisko Therapeutics Co., Ltd., has completed the dosing of the first patient in tenosynovial giant cell tumor (TGCT) cohort of Phase Ib Trial for CSF-1R Inhibitor ABSK021.

This is a voluntary announcement made by the Company. The Group cannot guarantee that ABSK021 will ultimately be successfully marketed. Shareholders and potential investors of the Company are advised to exercise caution when dealing in the shares of the Company.

By order of the Board  
**Abbisko Cayman Limited**  
**Dr. Xu Yao-Chang**  
*Chairman*

Shanghai, 21 December 2021

*As at the date of this announcement, the board of directors of the Company comprises Dr. Xu Yao-Chang, Dr. Yu Hongping, Dr. Chen Zhui and Mr. Yeh Richard as executive directors; Dr. Xia Gavin Guoyao and Ms. Tang Yanmin as non-executive directors; and Dr. Sun Piaoyang, Mr. Sun Hongbin and Mr. Wang Lei as independent non-executive directors.*

## **Abbisko Therapeutics Completes Dosing of the First Patient in TGCT Cohort of Phase Ib Trial for CSF-1R Inhibitor ABSK021**

21 December, 2021, Shanghai – Abbisko Therapeutics Co., Ltd. (“**Abbisko Therapeutics**” hereafter) today announced completion of dosing of the first patient in the phase Ib clinical trial tenosynovial giant cell tumor (TGCT) cohort in China for ABSK021, an innovative CSF-1R inhibitor, which signifies the progression into dose expansion phase targeting the indication. The purpose of this cohort is to assess the safety, tolerability, and preliminary anti-tumor activity of ABSK021 in patients with TGCT.

### **About ABSK021**

ABSK021 is a novel, orally available, highly selective, and highly potent small molecule inhibitor of CSF-1R, independently developed by Abbisko Therapeutics. A number of studies have shown that blocking the CSF-1R signaling pathway could effectively modulate and change tumor microenvironment, relieve tumor immunosuppression, and synergize with other anti-cancer therapies such as immune checkpoint inhibitors to achieve tumor inhibition. It has been demonstrated in several clinical studies that the CSF-1R inhibitors, by inhibiting CSF-1R activity, could be used to treat TGCT, and to treat a variety of malignancies through combination with immuno-oncology and/or other therapeutic agents. As at the date of this press release, no CSF-1R inhibitor has been approved in China.

ABSK021 is the first selective CSF-1R inhibitor discovered by a Chinese company that has advanced into human clinical trial. A phase Ia dose escalation study has been completed in the U.S., which demonstrated excellent PK/PD and safety profile of ABSK021 in human.

Tenosynovial giant cell tumor (TGCT) is a nonmalignant joint or tendon sheath tumor, which may be locally invasive in some patients. TGCT affects synovial joints, mucous sacs, and tendon membranes, resulting in swelling, pain, stiffness, and decreased activity of the affected joints or limbs. At present, surgical resection is the standard treatment for TGCT. However, not all patients are suitable for surgical treatment. It is difficult to remove tumors of diffuse patients by surgery, which may possibly lead to severe joint damage and loss of function. The disease is prone to relapse and there is a serious lack of effective treatment methods. Innovative treatments are urgently needed. Studies have shown that the signal pathway mediated by CSF-1R is the main factor leading to abnormal cell proliferation in synovium and the development of giant cell tumor of tendon sheath.

## **About Abbisko Therapeutics**

Founded in April 2016, Abbisko Therapeutics Co., Ltd., a subsidiary of Abbisko Cayman Limited (Stock Code: 2256.HK), is an oncology focused biopharmaceutical company founded in Zhangjiang, Shanghai, dedicated to discovering and developing innovative medicines to treat unmet medical needs in China and around the world. The company was established by a group of seasoned drug hunters with rich R&D and managerial expertise from top multinational pharmaceutical companies. Since its founding, Abbisko Therapeutics has built up an extensive pipeline of 14 innovative small molecule programs focused on precision oncology and immuno-oncology, including six clinical stage assets and eight pre-clinical stage assets. As of today, Abbisko Therapeutics has received ten IND or clinical trial approvals in four countries and regions.

Please visit [www.abbisko.com](http://www.abbisko.com) for more information.

## **Forward-Looking Statements**

The forward-looking statements made in this article relate only to the events or information as of the date on which the statements are made in this article. Except as required by law, we undertake no obligation to update or revise publicly any forward-looking statements, whether as a result of new information, future events or otherwise, after the date on which the statements are made or to reflect the occurrence of unanticipated events. You should read this article completely and with the understanding that our actual future results or performance may be materially different from what we expect. In this article, statements of, or references to, our intentions or those of any of our Directors or our Company are made as of the date of this article. Any of these intentions may alter in light of future development.